Dynavax Technologies (DVAX) News Today

Swedbank AB lowered its holdings in shares of Dynavax Technologies Co. (NASDAQ:DVAX - Free Report) by 14.8% in the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 256,700 shares of the biopharmaceutical company's stock after selling 44,700 shares during the period.

Dynavax Technologies Co. (NASDAQ:DVAX - Free Report) - Stock analysts at HC Wainwright lifted their FY2024 earnings per share estimates for Dynavax Technologies in a research note issued to investors on Wednesday, August 7th. HC Wainwright analyst E. White now expects that the biopharmaceutical c

The Goldman Sachs Group cut their target price on Dynavax Technologies from $20.00 to $15.00 and set a "neutral" rating for the company in a research note on Thursday.

HC Wainwright restated a "buy" rating and issued a $29.00 target price on shares of Dynavax Technologies in a research note on Wednesday.

Dynavax Technologies (NASDAQ:DVAX) Hits New 12-Month Low at $10.02

Swedbank AB purchased a new position in shares of Dynavax Technologies Co. (NASDAQ:DVAX - Free Report) in the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 301,400 shares of the biopharmaceutical company's stock, valued at

Burney Co. cut its position in Dynavax Technologies Co. (NASDAQ:DVAX - Free Report) by 25.3% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 400,324 shares of the biopharmaceutical company's stock after

Dynavax Technologies (NASDAQ:DVAX) will be releasing earnings after the market closes on Tuesday, August 6, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=368004)

State Board of Administration of Florida Retirement System decreased its holdings in Dynavax Technologies Co. (NASDAQ:DVAX - Free Report) by 60.2% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 38,067

Mizuho Markets Americas LLC boosted its stake in Dynavax Technologies Co. (NASDAQ:DVAX - Free Report) by 16.9% in the 1st quarter, according to its most recent filing with the SEC. The fund owned 852,057 shares of the biopharmaceutical company's stock after purchasing an additional 123,300 shares d

Dynavax Technologies Co. (NASDAQ:DVAX - Get Free Report) was the recipient of a large drop in short interest during the month of June. As of June 30th, there was short interest totalling 18,060,000 shares, a drop of 18.1% from the June 15th total of 22,060,000 shares. Based on an average daily trading volume, of 2,260,000 shares, the short-interest ratio is currently 8.0 days.

BNP Paribas Financial Markets lessened its holdings in shares of Dynavax Technologies Co. (NASDAQ:DVAX - Free Report) by 26.8% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 302,472 shares of the biop

Dynavax Technologies (NASDAQ:DVAX) Sets New 1-Year Low at $10.48

Nordea Investment Management AB grew its stake in shares of Dynavax Technologies Co. (NASDAQ:DVAX - Free Report) by 23.0% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 393,781 shares of the biopharmaceu

Vanguard Group Inc. raised its holdings in shares of Dynavax Technologies Co. (NASDAQ:DVAX - Free Report) by 1.4% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 9,275,788 shares of the biopharmaceutical compa

HC Wainwright reaffirmed a "buy" rating and set a $29.00 price objective on shares of Dynavax Technologies in a research report on Friday.

Goldman Sachs Group Inc. raised its stake in shares of Dynavax Technologies Co. (NASDAQ:DVAX - Free Report) by 21.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 3,597,139 shares of the biopharmaceutical c

Fisher Asset Management LLC cut its position in shares of Dynavax Technologies Co. (NASDAQ:DVAX - Free Report) by 16.3% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 1,390,428 shares of the biopharmaceutical company's stock after se

Dynavax Technologies Co. (NASDAQ:DVAX - Get Free Report) was the recipient of a significant drop in short interest in the month of May. As of May 31st, there was short interest totalling 21,390,000 shares, a drop of 5.8% from the May 15th total of 22,700,000 shares. Based on an average daily trading volume, of 2,100,000 shares, the short-interest ratio is currently 10.2 days.

Parkman Healthcare Partners LLC acquired a new position in Dynavax Technologies Co. (NASDAQ:DVAX - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 253,947 shares of the biopharmaceut

Kynam Capital Management LP grew its holdings in Dynavax Technologies Co. (NASDAQ:DVAX - Free Report) by 202.9% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 1,514,383 shares of the biopharmaceutical company's stock after acquiring an add

Rafferty Asset Management LLC increased its holdings in shares of Dynavax Technologies Co. (NASDAQ:DVAX - Free Report) by 13.4% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 540,319 shares of the biopharmaceutical c

Affinity Asset Advisors LLC grew its holdings in shares of Dynavax Technologies Co. (NASDAQ:DVAX - Free Report) by 50.0% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 300,000 shares of t

Rhenman & Partners Asset Management AB boosted its position in shares of Dynavax Technologies Co. (NASDAQ:DVAX - Free Report) by 14.3% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 800,000 shares of the biop

Dynavax Technologies Co. (NASDAQ:DVAX - Get Free Report) was the recipient of a significant increase in short interest in May. As of May 15th, there was short interest totalling 22,700,000 shares, an increase of 15.7% from the April 30th total of 19,620,000 shares. Based on an average daily volume of 2,070,000 shares, the short-interest ratio is currently 11.0 days.

Dimensional Fund Advisors LP lifted its holdings in Dynavax Technologies Co. (NASDAQ:DVAX - Free Report) by 7.8% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 4,032,139 shares of the biopharmaceutical company

StockNews.com downgraded Dynavax Technologies from a "buy" rating to a "hold" rating in a research note on Tuesday.

Trexquant Investment LP lifted its stake in shares of Dynavax Technologies Co. (NASDAQ:DVAX - Free Report) by 51.3% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 263,912 shares of the biopharmaceutical company's stock aft

StockNews.com raised Dynavax Technologies from a "hold" rating to a "buy" rating in a research report on Monday.

BNP Paribas Financial Markets boosted its position in shares of Dynavax Technologies Co. (NASDAQ:DVAX - Free Report) by 23.6% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 413,409 shares of the biopharmaceut

Great Lakes Advisors LLC lessened its stake in shares of Dynavax Technologies Co. (NASDAQ:DVAX - Free Report) by 34.6% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 488,772 shares of the biopharmac

Dynavax Technologies Co. (NASDAQ:DVAX - Free Report) - Research analysts at William Blair issued their Q1 2025 EPS estimates for Dynavax Technologies in a note issued to investors on Tuesday, May 14th. William Blair analyst M. Phipps anticipates that the biopharmaceutical company will earn $0.03